ClinicalTrials.Veeva

Menu

A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy

N

National Cancer Center (NCC)

Status

Completed

Conditions

Pancreatic Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT04281511
NCC2019-0034

Details and patient eligibility

About

  1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center.
  2. To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center

Full description

  1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample
  2. Collect data of Biomarker for pancreatic cancer
  3. Compare with Big data and Cohort study in National cancer center
  4. The number of subjects is changed by statistical consideration. 218->238

Enrollment

238 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pathologically Confirmed Pancreatic Cancer Patients

Exclusion criteria

  • Subjects who do not agree with the study

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems